INSIDE THIS ISSUE: PARKINSON'S DISEASE
published May 31, 2006
Top News Alerts: Product Updates, Deals & Financings
Featured Topic: Current Parkinson's Treatments & Clinical Trials
Highlights of: The Neurotech Industry Conference
Featured Company: Neurologix (NRGX.OB)
MARKET SUMMARY: NEUROCRINE TAKES A HIT, NORTHSTAR MAKES MARKET DEBUT
NeuroInsights’ first annual Neurotech Industry Conference on May 18th drew a full house. Participants enjoyed presentations and panels from over 40 speakers and gave enthusiastic feedback about the high-level networking with key industry players (See Highlights, page 2). Elan (ELN) was up yet again this month as all signs continue to point to an FDA approval of the reintroduction of their multiple sclerosis drug Tysabri at the end of June. CEO Kelly Martin, indicated Elan and partner, Biogen Idec (BIIB), may raise the price of Tysabri treatment depending on final labeling related to potential risks...
HIGHLIGHTS OF THE NEUROTECH INDUSTRY CONFERENCE 2006
The recent Neurotech Industry Investing and Business Conference organized and hosted by NeuroInsights showcased scientists, executives, and investors analyzing critical factors driving the development of new drugs, devices and diagnostics for the brain and nervous system. Full Story
EMERGING TREATMENTS FOR PARKINSON’S
Subscribe now for these articles and much much more...
Parkinson's disease is a movement disorder first described by London physician James Parkinson in 1817 in his "Essay on the Shaking Palsy." It is an idiopathic, slowly progressive, degenerative CNS illness characterized by slow to diminished movement, muscular rigidity, postural instability, and a resting tremor. Parkinson's disease (PD) is one of the most common neurodegenerative diseases of the elderly. Neurodegenerative diseases are a heterogeneous collection of brain disorders where a particular group of neurons dies prematurely. The group traditionally includes dementias (such as Alzheimer's), Parkinson's, ALS or Lou Gehrig's disease, cerebellar degeneration, Huntington's disease, and prion diseases such as Creutzfeldt-Jacob and its variants. These diseases have some features in common and all ultimately lead to death, but their time course and therapy vary widely...
NEUROLOGIX (NRGX.OB): GENE THERAPY MAKING A COMEBACK
Neurologix (NRGX.OB), founded in 1999 by Dr. Matthew During and Dr. Michael Kaplitt, is not afraid to say it is a gene therapy company. When the company was founded, gene therapy was all the rage, but soon afterwards serious side-effects including at least one case of a deadly immune reaction appeared in human trials. The trials were put on hold and gene therapy was shunned by investors and companies alike. It now appears, not surprisingly perhaps, that those who persisted in its arduous development will reap the rewards....